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Abstract: Heparin-induced thrombocytopenia (HIT) is an immunologic drug reaction 
characterized by paradoxical association with venous and arterial thrombosis. The syndrome 
is caused by IgG antibodies that are reactive against complexes of platelet factor 4 and heparin. 
Fondparinux does not bind to platelet factor 4, is structurally too short to induce an antibody 
response, and could in theory be a useful agent to treat HIT. A 69-year-old white female pre-
sented with a lower extremity extensive iliofemoral deep vein thrombosis after a right total knee 
arthroplasty and was subsequently found to have a pulmonary embolism. The patient was noted 
to have heparin ﬂ  ushes during her operation. Her platelet drop decreased 50% from baseline 
during initiation of antithrombotic therapy. She was started on subcutaneous fondaparinux 7.5 mg 
once daily injection. Her serotonin release assay and enzyme-linked immunosorbent assay for 
heparin antibodies were positive for HIT. Her platelet count nadir was 60 × 103/mm3 on day 5 
and the platelet count rebounded after 8 days of fondaparinux therapy. No recurrent thrombotic 
or bleeding events were noted throughout her therapy. Anecdotal reports have shown that 
fondaparinux can be a useful agent to treat HIT with or without thrombosis.
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Fondaparinux (GlaxoSmithKline, Middlesex, UK) is a new synthetic pentasaccaride 
that binds to antithrombin and potentiates antithrombin inhibition of factor Xa. It does 
not bind to platelet factor 4 and is unlikely to cause immunoallergic heparin-induced 
thrombocytopenia (HIT) (Dager et al 2004). Data had shown that fondaparinux is 
structurally too short to induce an antibody response and could be a useful agent to 
treat HIT (Eﬁ  rd et al 2006).
Case report
A 69-year-old white female presented to the Clinical Thrombosis Center on March 
5th, 2007, with a lower extremity extensive iliofemoral deep vein thrombosis (DVT) 
conﬁ  rmed by Doppler ultrasonography, after a right total knee arthroplasty on February 
19th, 2007. The patient had received aspirin prophylaxis 325 mg twice daily during the 
postoperative period. She was started on subcutaneous enoxaparin injection (sanoﬁ  -
aventis, Paris, France) at 75 mg twice daily and warfarin 7.5 mg once daily by the 
emergency department on March 4th, 2007.
Her medical history included hypertension, degenerative joint disease, and dys-
lipidemia. Her past surgical histories included 3 cesarean sections, hysterectomy, 
and parathyroidectomy. Her family history was negative for venous thromboembolic Therapeutics and Clinical Risk Management 2008:4(3) 654
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disease. Her medications included verapamil, triamterene/
hydrochlorothiazide, lovastatin, aspirin, naproxen sodium, 
acetaminophen, vitamin C, vitamin E, and a multivita-
min. The patient denied any shortness of breath, pleurisy, 
hemoptysis, or low grade fevers or chills, but complained 
of dyspnea on exertion. Her blood pressure was 143/76 mm 
Hg, temperature 97.2 °F, pulse 96, and oxygen saturation 
97%. Her laboratories results were signiﬁ  cant for white 
count 9.2 × 103/mm3, hematocrit 37.7%, platelet count 
81 × 103/mm3. Her prothrombin time (PT), activated partial 
thromboplastin time (aPTT), and liver function tests were all 
within normal limits. Her serum creatinine was 0.8 mg/dl. 
On physical examination, the right lower extremity showed 
some severe swelling, especially of the knee. Her lungs were 
clear to auscultation and cardiovascular examination showed 
regular rate and rhythm.
Her last platelet count was done preoperatively on Febru-
ary 9th, 2007 and revealed a normal platelet count of 293 × 
103/mm3. In view of her thrombocytopenia, the patient was 
admitted to the hospital for closer observation. Her enoxa-
parin injection was discontinued and fondaparinux injection 
was started subcutaneously at a dose of 7.5 mg daily as a 
bridge to dose-adjusted warfarin, which was continued at 5.0 mg 
daily. She was also worked up for HIT and disseminated 
intravascular coagulation (DIC).
The patient came into the clinic following her hospitaliza-
tion for her DVT and thrombocytopenia on March 9th, 2007. 
The patient complained of pain in her knees, increased cough 
and continued dyspnea on exertion. She had no complaints 
of pleurisy, hemoptysis, fevers or chills. In view of her 
continued dyspnea on exertion, a ventilation/perfusion scan 
was ordered. The leg swelling on her right was better and 
she reported less pain on the leg, and the patient was advised 
to place compression stockings on the affected extremity. 
There was no evidence of limb-gangrene or warfarin-induced 
skin necrosis.
Her ﬁ  ngerstick international normalized ratio (INR) was 
5.1 and she was on subcutaneous fondaparinux injection 
7.5 mg daily (5 doses given to date) and warfarin 5 mg daily. 
She was also on acetaminophen (Tylenol®) 500 mg every 
4 hours for her leg pain. Her platelet count was 60 × 103/mm3 
and she tested positive for heparin-induced antiplatelet 
antibodies. The patient refused to be re-admitted to the 
hospital for treatment of suspected HIT-associated thrombosis 
(HITT) with parenteral direct thrombin inhibitors, and after 
careful discussion with the patient and her family, she agreed 
to continue treatment on an outpatient basis under careful 
supervision with subcutaneous fondaparinux. The patient 
was informed to hold her warfarin and continue fondaparinux 
until the next clinic visit. She had a repeat INR and complete 
blood count check on March 12th, 2007. The patient was also 
advised to stop her Tylenol.
Her platelet count was 100 × 103, ﬁ  ngerstick INR 3.6, 
hematocrit 38.8% at the next visit. She restarted warfarin at 
2.5 mg daily. The serotonin release assay (SRA) and repeat 
enzyme-linked immunosorbent assay (ELISA) HIT studies 
were still pending at the point of consultation. The right 
leg swelling and inner thigh calf erythema were slightly 
decreased. The patient was advised to place compression 
stockings. We were informed by the patient’s daughter that 
the patient had received heparin ﬂ  ushes during the time of 
her operation.
The patient had her follow up 4 days later. Her V/Q 
scan showed a high probability for pulmonary embolism. 
The platelet count was 123 × 103/mm3, hematocrit 34.4%. 
HITT was conﬁ  rmed by high pretest probability (signiﬁ  cant 
thrombocytopenia of 50% from baseline associated with 
unfractionated heparin (UFH) and low molecular weight 
heparin (LMWH) exposure at most 25 days from baseline 
associated with venous thrombosis) and positive ELISA 
HIT results and SRA done on March 9th, 2007 (86%). Her 
ﬁ  ngerstick INR was 4.1. Her warfarin dose was adjusted and 
fondaparinux was discontinued. She was counseled against 
any future use of heparins or LMWHs in view of her history 
of HITT. Her platelet counts are shown in Table 1.
Discussion
HIT is an immunologic drug reaction characterized by 
paradoxical association with venous and arterial thrombo-
sis (Warkentin et al 1995; Warkentin and Kelton 2001). 
The venous thromboembolic events dominate over arterial 
thromboembolic events at a ratio of approximately 4:1 
(Warkentin and Kelton 1996; Wallis et al 1999; Kelton 
2005). The syndrome is caused by IgG antibodies that are 
reactive against complexes of platelet factor 4 and heparin 
(Amiral et al 1992).
HIT occurs 5–10 days post exposure to heparin. 
Thrombocytopenia can occur quickly, even minutes to 
hours in patient who have HIT antibodies post previous 
exposure to heparin (Warkentin 1999). HIT antibody for-
mation is accompanied by an unexplained platelet count 
fall (usually 50% fall, even if the platelet count nadir 
remains 150 × 109/L), or by skin lesions at heparin injection 
sites or acute systemic reactions (eg, chills, cardiorespira-
tory distress) after intravenous heparin bolus administration 
(Warkentin and Greinacher 2004).The incidence of HIT Therapeutics and Clinical Risk Management 2008:4(3) 655
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varies with the patient type (Warkentin et al 2000) and the 
heparin preparation (Powers et al 1984). The frequency of 
HIT is greater in surgical than in medical patients. In ortho-
paedic patients given subcutaneous prophylactic heparin, 
the incidence is approximately 5% with UFH and 0.5% with 
LMWH (Warkentin et al 2000). HIT can occur in 0.5% to 1% 
of patients who receive lower doses of heparin (subcutaneous 
or ﬂ  ushes) or even the tiny amounts that leach from heparin-
coated catheters (Laster and Silver 1988; Kadidal et al 1999; 
Mayo et al 1999; Lawrence et al 2002). Only a minority of 
patients who form HIT antibodies during heparin therapy 
develop clinical HIT. Most patients who form HIT antibodies 
develop seroconversion without thrombocytopenia or throm-
bosis. The risk of HITT occurs predominantly in patients who 
also develop thrombocytopenia (Warkentin 1999).
The management of HIT includes the discontinuation 
of UFH and LMWH therapy, and the use of an alternative 
agent such as the heparinoids and the direct thrombin inhibi-
tors. An alternative agent is required as the patient is still at 
substantial thrombosis (Kuo and Kovacs 2005) and in one 
retrospective analysis, 40%–61% of patients with HIT suf-
fered from thrombosis after heparin cessation (Wallis et al 
1999). Warfarin therapy is not recommended for the initial 
treatment of HIT until the platelet count is above 100 × 109/L 
as it may lead to warfarin-induced venous limb gangrene 
and skin necrosis (Warkentin et al 1997: Klein et al 2004; 
Srinivasan et al 2004).
The direct thrombin inhibitors lepirudin, argatroban, and 
bivalirudin have been used for the treatment of HIT (Eﬁ  rd and 
Kocker 2006). These agents have chemical structures, which 
are different from UFH and LMWH and do not generate or 
cross react with antiheparin-platelet factor 4 antibodies (or 
HIT antibodies) and are effective and safe for the prophy-
laxis or treatment of thrombosis (Hassell 2005). However, 
their use is complicated by the need for continuous intrave-
nous infusion administration, monitoring using aPTT, dose 
modiﬁ  cation based on hepatic or renal function, and acquisi-
tion cost. Hence, other HIT treatment options are essential 
(Eﬁ  rd and Kocker 2006).
Fondaparinux is a synthetic pentasaccharide that catalyzes 
the inhibition of factor Xa by antithrombin, resulting in the 
inhibition of thrombin generation (Kuo and Kovacs 2005). 
Data had shown that an increased risk for HIT-related antigen 
production is dependent on molecular weight and length of 
polysaccarides (2.4 kDa and 10 saccharide units, respec-
tively); and structural components for UFH and LMWH are 
above the minimum requirements for increasing the risk of 
these antigens (Table 2). Amiral and colleagues (1997) had 
found no cross reactivity of fondaparinux with antibodies to 
the heparin-PF4 complexes in his in vitro assay. Warkentin 
and colleagues (2005) found that anti-PF4/heparin antibod-
ies were generated at similar frequencies in patients treated 
with fondaparinux or enoxaparin (Warkentin et al 2005). 
Although antibodies reacted equally well in vitro against 
Table 1 Platelet counts and clinical course during the observed period
Date Platelet count (×103)/ mm3 Remarks
2/9/2007 293 Baseline platelet count.
2/19/2007 Right total knee arthroplasty with aspirin 325 mg BID given for thromboprophylaxis.
3/4/2007 Doppler CUS with extensive right lower extremity ileofemoral DVT. Patient treated with 
enoxaparin 75 mg SQ BID and warfarin 7.5 mg daily. Patient complaining of dyspnea on exertion.
3/5/2007 81 First visit to the Clinical Thrombosis Center and ﬁ  rst platelet count done postoperation. 
Enoxaparin discontinued, fondaparinux 7.5 mg SQ daily started, warfarin continued, and patient 
admitted to hospital. ELISA and SRA studies for HIT ordered.
3/6/2007 93 Platelet counts done while hospitalized. Fondaparinux and warfarin continued.
3/7/2007 94 Platelet counts done while hospitalized. Patient discharged on fondaparinux 7.5 mg SQ daily 
and warfarin 7.5 mg daily.
3/9/2007 60 Platelet count done in the Clinical Thrombosis Center post-hospitalization. ELISA test positive 
for heparin-induced antiplatelet antibodies. Patient refuses re-hospitalization. Warfarin 
discontinued, fondaparinux 7.5 mg continued. Ventilation-perfusion scan ordered.
3/12/2007 100 Warfarin restarted at 2.5 mg daily, fondaparinux continued.
3/16/2007 123 Repeat ELISA and SRA studies positive for HIT,   Ventilation-perfusion scan positive for pulmonary 
embolism, fondaparinux discontinued, ﬁ  ngerstick INR 4.1, warfarin dose adjusted.
3/20/2007 179 Patient doing well, no clinical VTE recurrence, continue dose-adjusted warfarin, target INR 2.5.
Abbreviations: BID, twice daily; CUS, cranial ultrascopography; ELISA, enzyme-linked immunosorbent assay; INR, international normalized ratio; SQ, subcutaneous; SRA, 
serotonin release assay; VTE, venous thromboembolism.Therapeutics and Clinical Risk Management 2008:4(3) 656
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PF4/UFH and PF4/LMWH, and sometimes weakly against 
PF4/danaparoid, none reacted against PF4/fondaparinux, 
including even those sera obtained from patients who formed 
antibodies during fondapaprinux treatment. Hence, despite 
similar immunogenicity of fondaparinux and LMWH, PF4/
fondaparinux, but not PF4/LMWH is recognized poorly by 
the antibodies generated, suggesting that the risk of HIT with 
fondaparinux, if likely, is very low. Recently, a single case 
report of HIT with the use of fondaparinux has been reported 
(Warkentin et al 2007).
Anecdotal reports have shown that fondaparinux could 
be a useful agent in the treatment of HIT (Lian et al 2003; 
Parody et al 2003; Bradner et al 2004; Herenberg et al 2004) 
and HITT (Kuo and Kovacs 2003; Rubin 2003).
Kuo and Kovacs (2003) administered fondaparinux to 
5 surgical patients who developed heparin/PF4 ELISA-conﬁ  rmed 
HIT after receiving UFH for venous thromboprophylaxis. 
Thrombocytopenia occurred between 6 and 10 days after 
the initiation of heparin anticoagulation and the platelet 
count nadir ranged from 5 × 109/L to 79 × 109/L. Pulmonary 
embolism (n = 2), deep vein thrombosis (n = 2), and left atrial 
and mechanical mitral valve thrombosis (n = 1) were noted. 
In all cases, UFH or LMWH was discontinued and patients 
were treated with subcutaneous injections of fondaparinux 
7.5 mg daily as soon as the clinical diagnosis of HIT was made 
and UFH therapy had stopped. All patients responded with the 
platelet count becoming normal between 2 and 9 days after 
the initiation of anticoagulation with fondaparinux. Warfarin 
was initiated (and fondaparinux continued) when the platelet 
count was 100 × 109/L. Fondaparinux was then discontinued 
when the target INR was 2.0 for two consecutive days. No 
recurrence of thombosis occurred during the therapy.
Rubin (2003) reported a case of fondaparinux use in a 
29-year-old pregnant female who had HIT during her ﬁ  rst 
trimester of pregnancy secondary to UFH treatment for 
pulmonary embolism. She had a platelet count drop of more 
than 50% from baseline after 5 days of treatment with UFH. 
The assay for HIT antibodies was positive. She was started on 
fondaparinux 2.5 mg subcutaneously twice daily. No further 
complications occurred throughout her pregnancy and the 
baby was born healthy without any problems with delivery.
Our patient presented with a large ileofemoral DVT and 
thrombocytopenia after major orthopedic surgery in which 
she was thromboprophylaxed with a weak antithrombotic 
agent, aspirin. She was treated with fondaparinux for HITT 
that was veriﬁ  ed by a high pretest probability as well as 
positive ELISA and SRA studies. Further evaluation revealed 
that the patient likely had a concurrent pulmonary embolism 
during her index event. Interestingly, her HITT could be due 
to the heparin ﬂ  ushes she had gotten during her surgery and 
aggravated by the LMWH (enoxaparin) that she received 
in the emergency department for initial treatment of her 
DVT, in which initial suspicion of HITT was missed. Our 
patient reported no complications or bleeding from the use 
of fondaparinux subcutaneous injections, and other than 
complete blood counts and INRs, no other routine monitoring 
was done, which enabled the patient to complete her course 
of treatment in the outpatient setting. Her platelets counts 
rebounded after 7 days of treatment and we are still follow-
ing her progress. Her last known platelet count on March 
20th, 2007 was 179 × 103. We had also used fondaparinux 
injection in 2 previous patients with suspected HIT with no 
further complications or bleeding, although their clinical 
course is less well described.
Conclusion
Heparin-induced thrombocytopenia (HIT) with or without 
thrombosis is an immunologic drug reaction caused by IgG 
antibodies that are reactive against complexes of platelet fac-
tor 4 and heparin. Antibodies against PF4/fondaparinux have 
been described during fondaparinux therapy and a single case 
report of HIT with the use of fondaparinux has been reported. 
However, unlike the approved agents that are used to treat 
HIT (argatroban, lepirudin, and bivalirudin), fondaparinux 
does not require routine laboratory monitoring. Anecdotal 
reports have shown that fondaparinux can be a useful agent 
to treat HIT or HITT, possibly in the outpatient setting, but 
further larger trials are needed to assess the above.
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